课题基金 / 基金详情

TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES

TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
通过异种嵌合分子进行移植免疫调节
批准号:
6838746
负责人:
Rafik MARK GHOBRIAL
金额:
$26.69万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-01 至 2007-12-31

项目摘要

项目成果

Rafik MARK GHOBRIAL的其他基金

相似基金

相关文献

中文摘要
翻译
超出所提供的空间我们试图开发一种临床适用的策略,在接受同种异体I类MHC分子治疗的同种异体移植受者中诱导“真正的”移植耐受。我们在大鼠同种异体心脏移植模型上的初步发现为这一提议提供了基础。我们假设:(I)异体嵌合诱导的耐受,作为受体MHC I类分子所展示的供体类型免疫原性表位的间接递呈的函数,适用于遗传多样性的移植受体;(Ii)异基因MHC I类分子的间接递呈诱导产生一组独特的调节性T细胞,维持并转移一种慢性排斥无“真正”耐受的状态。我们提出了以下具体目标:1.确定不同的AIIochimal分子诱导耐受的要求。假设:受体类型的同种异体嵌合体I类分子表现出供体类型的免疫原性表位,可诱导对供体类型同种异体移植物的‘真’耐受。不同毒株组合中的多个同种嵌合分子将通过PCR基因SOEing构建,以确定I类MHC多态区域的关键免疫原性表位。在受体I类抗原上显示供体主导表位的融合分子将接受测试,以确定是否有能力诱导“真正的”慢性无排斥耐受。2.间接提呈AIIochimal[c%_Ju]-RT1 Aa I类MHC分子分析AIIo免疫调节作用。假设:血液凝固疗法通过间接途径偏离宿主对同种异体器官移植的免疫反应。对同种异体移植物存活至关重要的免疫原性/隐蔽自身表位的精细映射将被执行。通过使用宿主或供体类型的树突状细胞在体外与供体野生型或[cqh_/U]-RT1.A分子冲击的宿主或供体类型的树突状细胞,将解决NAFVE或预置的T细胞反应的间接同种嵌合偏离。在这个模型中,调节性T细胞的产生可能是一个关键的耐受机制,将通过研究未成熟的肝树突状细胞间接向CD4+T细胞递送同种嵌合分子来在体外探索这一机制。在体内,用造血生长因子FIt3L刺激肝脏树突状细胞的同种异体刺激能力/成熟度,以消除门静脉内异体嵌合输注后间接诱导的耐受。3.研究间接免疫反射诱导的独特调节性T细胞群的特征。假设:由间接同种异体识别诱导的调节性T细胞协调获得耐受性和消除慢性排斥反应。我们将进行体内和体外调节性T细胞的表型和功能表征。它们介导CD8+细胞毒性T细胞抑制或直接抑制树突状细胞提呈抗原的能力将在体外进行分析。在细胞因子补充和/或抑制的同时,Transwell实验将分析细胞与细胞接触的要求与特定的细胞因子要求。通过分析(I)偏离宿主抗供体同种异体抗体反应诱导的血管“调节”,(Ii)细胞保护分子的上调,以及(Iii)移植物浸润性单个核细胞的功能状态,将研究独特的调节性T细胞协调抑制慢性排斥反应。>性能网站========================================Section End===========================================
英文摘要
EXCEED THE SPACE PROVIDED We seek to develop a clinically applicable strategy to induce a "true" transplantation tolerance in allograft recipients treated with allochimeric Class I MHC molecules. Our preliminary findings in a rat cardiac allograft model provide the foundation of this proposal. We hypothesize that: (i) allochimeric-induced tolerance, as a function of indirect presentation of donor-type immunogenic epitopes displayed by recipient MHC Class I molecules, is applicable to genetically diverse graft recipients; (ii) indirect presentation of allochimeric MHC Class I molecules induces generation of a unique population of regulatory T cells that maintain and transfer a state of chronic rejection-free "true" tolerance. We propose the following specific aims: 1. To Define the Requirements of Different AIIochimeric Molecules to Induce Tolerance. Hypothesis: Recipient-type allochimeric class I molecules that exhibit donor-type immunogenic epitopes induce '_true" tolerance to donor-type allografts. Multiple allochimeric molecules, in different strain combinations, will be constructed by PCR gene SOEing, to define critical immunogenic epitopes in the polymorphic regions of class I MHC. AIIochimeric molecules that display donor-dominant epitopes on recipient-class I antigens will be tested for the ability to induce a "true" chronic rejection-free tolerance. 2. To Analyze AIIoimmune Modulation by Indirect Presentation of AIIochimeric [c%_JU]-RT1.Aa Class I MHC Molecules. Hypothesis: AIIochimeric therapy deviates host immune responses to organ allografts via indirect pathway. Fine mapping of immunogenic/cryptic self-epitopes that are critical for allograft survival will be performed. Indirect allochimeric deviation of nafve or primed T cell responses will be addressed by employing host or donor-type dendritic cells that have been pulsed in vitro with donor wild-type or [cqh_/U]-RTl.A a molecules. AIIochimeric generation of regulatory T cells, a possible key tolerogenic mechanism in this model, will be probed in vitro by studying immature hepatic dendritic cells that indirectly present allochimeric molecules to CD4+ T cells. In vivo stimulation of hepatic dendritic cell allostimulatory capacity/maturity will be investigated by using FIt3L, a heamatopoietic growth factor, to abrogate indirectly induced tolerance after intra-portal allochimeric infusion. 3. To Characterize the Unique Population of Regulatory T Cells Induced by Indirect AIIorecoflnition. Hypothesis: Regulatory T cells that are induced by indirect allorecognition orchestrate the acquisition of tolerance and abrogation of chronic rejection. We will perform in vivo and ex vivo phenotypic and functional characterization of regulatory T cells. Their ability to mediate CD8+ cytotoxic T cells inhibition or directly suppress antigen presentation by dendritic cells will be analyzed in vitro. Transwell experiments in parallel with cytokine supplementation and/or inhibition, will analyze the requirement of cell-cell contact vs. specific cytokine requirement. The unique regulatory T cell orchestrated inhibition of chronic rejection will be investigated by analyzing (i) vascular "accommodation" induced by deviated host anti-donor alloantibody responses, (ii) upregulation of cytoprotective molecules, and (iii) functional status of graft-infiltrating mononuclear cells. > PERFORMANCE SITE ========================================Section End===========================================
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
4/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE)
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
海外基金